Unknown PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT00563173

Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients

A Phase I/IIa Open-Label, Dose Ranging, Parallel, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C® in Combination With Electroporation in Chronic HCV Genotype 1 Infected and Treatment Naïve Patients With Low Viral Load

Sponsor: Inovio Pharmaceuticals

Conditions Chronic Hepatitis C Virus Infection

Interventions CHRONVAC-C®

Updated 5 times since 2017 Last updated: Feb 9, 2010 Started: Oct 31, 2007 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Chronic Hepatitis C Virus Infection, this trial is ongoing. The trial is conducted by Inovio Pharmaceuticals and has accumulated 5 data snapshots since 2007. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Oct 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Inovio Pharmaceuticals
Tripep AB

Data source: Tripep AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stockholm, Sweden